Cargando…

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab

Background: Many clinical factors can contribute to the efficacy of medical therapy in Inflammatory Bowel Disease (IBD). We assessed their effects on the efficacy of vedolizumab therapy in a cohort of patients with IBD. Methods: We conducted a retrospective study on patients between 18 and 80 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Bincy P., Fan, Christopher, Thurston, Theresa, Moskow, Joshua, Malaty, Hoda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674273/
https://www.ncbi.nlm.nih.gov/pubmed/38004241
http://dx.doi.org/10.3390/nu15224847
_version_ 1785149690117881856
author Abraham, Bincy P.
Fan, Christopher
Thurston, Theresa
Moskow, Joshua
Malaty, Hoda M.
author_facet Abraham, Bincy P.
Fan, Christopher
Thurston, Theresa
Moskow, Joshua
Malaty, Hoda M.
author_sort Abraham, Bincy P.
collection PubMed
description Background: Many clinical factors can contribute to the efficacy of medical therapy in Inflammatory Bowel Disease (IBD). We assessed their effects on the efficacy of vedolizumab therapy in a cohort of patients with IBD. Methods: We conducted a retrospective study on patients between 18 and 80 years of age with ulcerative colitis (UC) or Crohn’s disease (CD) who were seen in the IBD program at Houston Methodist in Houston, TX and treated with vedolizumab for at least 6 months from 2018 to 2022. We investigated factors prior to the initiation of therapy that best predicted treatment response, with an emphasis on vitamin D levels and examined several variables including patients’ demographics and clinical information on disease location and severity and nutritional status before and after the initiation of vedolizumab. Post-treatment data were gathered after a minimum of 6 months of vedolizumab therapy. The clinical parameters used for the study were the Harvey–Bradshaw Index for CD and the Activity Index for UC. Results: There were 88 patients included in our study of whom 44 had CD and 44 had UC.; median age was 39.5 (31.0, 53.25) years; 34% patients were male; and 80.7% were Caucasian. All patients received an induction dosing of 300 mg vedolizumab at 0, 2, and 6 weeks then maintenance dosing as standard of care every 8 weeks. Among UC patients with vitamin D ≥ 30 ng/mL at the initiation of vedolizumab therapy, UC Endoscopic Index of Severity (UCEIS) scores after 6 months of therapy were significantly lower than in those who had low pre-treatment vitamin D levels (1.5 vs. 3.87, p = 0.037). After treatment, vitamin D levels improved more significantly in the higher pre-treatment vitamin D group, with a median level of 56 ng/mL, than in the lower pre-treatment vitamin D group, with a median level of only 31 ng/mL (p = 0.007). In patients with CD with vitamin D ≥ 30 ng/mL at the initiation of vedolizumab therapy, we found higher iron saturation (12 vs. 25%, p = 0.008) and higher vitamin B12 levels (433.5 vs. 885 pg/mL, p = 0.003) than in those with vitamin D < 30 ng/mL. After treatment, CD patients with high pre-treatment vitamin D levels had significantly higher vedolizumab levels (27.35 vs. 14.35 μg/mL, p = 0.045) than those with low pre-treatment vitamin D. Post-treatment scores and inflammatory markers in CD patients (HBI, CRP, ESR, and SES-CD) were lower in those who had lower baseline vitamin D. Conclusions: Our results show higher pre-treatment vitamin D levels predicted significant endoscopic improvement in patients with ulcerative colitis (UC). Improving vitamin D levels lowered C-reactive protein levels significantly in CD patients. Higher vitamin D levels were seen after treatment in both UC and CD patients. Vitamin D can play a role in clinical and endoscopic outcomes and should be assessed routinely and optimized in patients with IBD.
format Online
Article
Text
id pubmed-10674273
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106742732023-11-20 The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab Abraham, Bincy P. Fan, Christopher Thurston, Theresa Moskow, Joshua Malaty, Hoda M. Nutrients Article Background: Many clinical factors can contribute to the efficacy of medical therapy in Inflammatory Bowel Disease (IBD). We assessed their effects on the efficacy of vedolizumab therapy in a cohort of patients with IBD. Methods: We conducted a retrospective study on patients between 18 and 80 years of age with ulcerative colitis (UC) or Crohn’s disease (CD) who were seen in the IBD program at Houston Methodist in Houston, TX and treated with vedolizumab for at least 6 months from 2018 to 2022. We investigated factors prior to the initiation of therapy that best predicted treatment response, with an emphasis on vitamin D levels and examined several variables including patients’ demographics and clinical information on disease location and severity and nutritional status before and after the initiation of vedolizumab. Post-treatment data were gathered after a minimum of 6 months of vedolizumab therapy. The clinical parameters used for the study were the Harvey–Bradshaw Index for CD and the Activity Index for UC. Results: There were 88 patients included in our study of whom 44 had CD and 44 had UC.; median age was 39.5 (31.0, 53.25) years; 34% patients were male; and 80.7% were Caucasian. All patients received an induction dosing of 300 mg vedolizumab at 0, 2, and 6 weeks then maintenance dosing as standard of care every 8 weeks. Among UC patients with vitamin D ≥ 30 ng/mL at the initiation of vedolizumab therapy, UC Endoscopic Index of Severity (UCEIS) scores after 6 months of therapy were significantly lower than in those who had low pre-treatment vitamin D levels (1.5 vs. 3.87, p = 0.037). After treatment, vitamin D levels improved more significantly in the higher pre-treatment vitamin D group, with a median level of 56 ng/mL, than in the lower pre-treatment vitamin D group, with a median level of only 31 ng/mL (p = 0.007). In patients with CD with vitamin D ≥ 30 ng/mL at the initiation of vedolizumab therapy, we found higher iron saturation (12 vs. 25%, p = 0.008) and higher vitamin B12 levels (433.5 vs. 885 pg/mL, p = 0.003) than in those with vitamin D < 30 ng/mL. After treatment, CD patients with high pre-treatment vitamin D levels had significantly higher vedolizumab levels (27.35 vs. 14.35 μg/mL, p = 0.045) than those with low pre-treatment vitamin D. Post-treatment scores and inflammatory markers in CD patients (HBI, CRP, ESR, and SES-CD) were lower in those who had lower baseline vitamin D. Conclusions: Our results show higher pre-treatment vitamin D levels predicted significant endoscopic improvement in patients with ulcerative colitis (UC). Improving vitamin D levels lowered C-reactive protein levels significantly in CD patients. Higher vitamin D levels were seen after treatment in both UC and CD patients. Vitamin D can play a role in clinical and endoscopic outcomes and should be assessed routinely and optimized in patients with IBD. MDPI 2023-11-20 /pmc/articles/PMC10674273/ /pubmed/38004241 http://dx.doi.org/10.3390/nu15224847 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abraham, Bincy P.
Fan, Christopher
Thurston, Theresa
Moskow, Joshua
Malaty, Hoda M.
The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
title The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
title_full The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
title_fullStr The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
title_full_unstemmed The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
title_short The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
title_sort role of vitamin d in patients with inflammatory bowel disease treated with vedolizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674273/
https://www.ncbi.nlm.nih.gov/pubmed/38004241
http://dx.doi.org/10.3390/nu15224847
work_keys_str_mv AT abrahambincyp theroleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT fanchristopher theroleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT thurstontheresa theroleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT moskowjoshua theroleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT malatyhodam theroleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT abrahambincyp roleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT fanchristopher roleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT thurstontheresa roleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT moskowjoshua roleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab
AT malatyhodam roleofvitamindinpatientswithinflammatoryboweldiseasetreatedwithvedolizumab